


The Prostate Core Mitomic Test Now You Can Know

The Prostate Core Mitomic Test

The Prostate Core Mitomic Test is a highly advanced, proprietary test based on the science of mitochondrial DNA (mtDNA).

Using existing prostate biopsy tissue, the Prostate Core Mitomic Test can determine the presence of malignant cells via a cancerization field effect by detecting underlying molecular alterations in normal appearing tissue.

And it's all performed quickly and easily with a simple lab test.



Advantages of the Prostate Core Mitomic Test

- Able to accurately classify a “true” negative, with a high negative predictive value of 91%.¹
- Utilizes cancerization field effect to identify molecular changes and enable detection of missed tumors, at a sensitivity of 84%.¹
- Detects elevated deletion levels in normal-appearing cells that coexist with a tumor.
- Uses existing biopsy tissue.
- Reduces cost by leveraging a simple, cost-effective, high throughput laboratory process.
- Simplifies testing.

The Prostate Core Mitomic Test is an effective and efficient aid for negative biopsy uncertainty.

Now you can know.


Providing Clinical Insight

A prostate cancer biopsy is neither an easy nor painless procedure.

It samples a small fraction of the prostate gland, potentially missing the tumor and contributing to a high false negative rate – even in second biopsies.

Until now.


With the highly sensitive Prostate Core Mitomic Test, you can know more by getting far more accurate, reliable results from previously obtained biopsy tissue.



How the Prostate Core Mitomic Test is Different

The Prostate Core Mitomic Test is based on the science of mtDNA. The unique structural and functional characteristics of mtDNA make it a highly attractive system for biomarker discovery and disease detection. In terms of cancer, large-scale deletions in mtDNA can indicate cellular changes that are associated with the development of the disease.

Increasing Numbers of Biopsy Cores Increases Performance Metrics




Study results indicate increasing performance of 3.4kb mitochondrial genome deletion with increasing number of cores assayed per patient.

Implementing the Prostate Core Mitomic Test

Consider the Prostate Core Mitomic Test for patients you suspect for prostate cancer, but who have a negative initial biopsy outcome including those who present with:

- Elevated PSA
- Rising PSA
- Irregular DRE
- Atypical small acinar proliferation (ASAP)
- High-grade prostatic intraepithelial neoplasia (HGPIN)
- Uncertain diagnosis of prostate cancer on biopsy including benign mimickers of prostate cancer

With the Prostate Core Mitomic Test's cancerization field effect, now you can know.



Our Company

Mitomics is the world leader in the research and development of mtDNA based biomarkers. Headquartered in Thunder Bay, Ontario, Canada, Mitomics is comprised of a team of business and research experts with a proven ability to discover and develop commercially viable molecular-based products to improve clinical insight and therapeutic decisions.



12635 E. Montview Blvd.
Aurora, CO 80045
Phone (888) 763-2644
PCMTsupport@mitomicsinc.com
www.mitomicsinc.com

CLIA #06D2020292
NPI #1528364056

Prostate Core Mitomic Test or one or more of its components was developed and its performance characteristics determined by Mitomics. It has not been approved by the Food and Drug Administration (FDA). The FDA has determined that such approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. Mitomics is regulated under the Clinical Laboratory Improvement Act (CLIA) of 1988 as qualified to perform high complexity clinical testing.

Prostate Core Mitomic Test, Mitomic, Mitomics, and Empowering Clinical Insight are trademarks of Mitomics Inc.

© 2011 Mitomics Inc. All rights reserved.

0211.0003. Rev 4.

References:

¹ Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay. Prostate Cancer and Prostatic Diseases 2010 Jan 19; <http://www.nature.com/pcan/journal/v13/n2/abs/pcan200964a.html>.